Profound Medical Corp PROF

Primary Symbol: T.PRN

Healthcare Medical Devices

Profound Medical Corp. is a Canada-based commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low -, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

TSX:PRN - Post by User

Profound Medical Corp > Insider Buying

<< Previous

Bullboard Posts

Next >>

Comment by HomerAndCompanyon Jul 03, 2021 9:38am

268 Views

Post# 33489413

RE:Insider Buying

Latest insider public market buy: June 22 (no selling since March) by Director Murielle Lortie, establishing a new position with 880 shares bought at $22.75.

Insider buys is recent months are still dwarfed by the selling done by CFO Aaron Davidson this March and December of last year. Any idea why the CFO was selling?

retiredcf wrote:

Profound Medical Corp.

On May 20, chief executive officer and chairman of the board Arun Menawat acquired 5,000 shares at an average cost per share of roughly US$18.71 increasing this specific account’s position to 246,988 shares. The cost of this purchase exceeded US$93,000.